Enrolling by invitationNCT01728402
Pathogenesis of Hematologic Malignancies
Studying Myelodysplastic/myeloproliferative disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- OHSU Knight Cancer Institute
- Principal Investigator
- Cristina Tognon, PhDOHSU Knight Cancer Institute
- Intervention
- blood draw, bone marrow procedure, or tissue biopsy(procedure)
- Enrollment
- 5000 target
- Eligibility
- 1 years · All sexes
- Timeline
- 2008
Study locations (1)
- OHSU Knight Cancer Institute, Portland, Oregon, United States
Collaborators
National Institutes of Health (NIH) · National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01728402 on ClinicalTrials.govOther trials for Myelodysplastic/myeloproliferative disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06315309Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell TransplantUniversity of Alabama at Birmingham
- RECRUITINGPHASE2NCT05564390MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)National Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06532084Sorafenib Relapase Prophylaxis After HCT With PTBCy RegimenSt. Petersburg State Pavlov Medical University
- RECRUITINGPHASE2NCT05788679A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDSKarolinska University Hospital
- RECRUITINGPHASE2NCT04493164CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeM.D. Anderson Cancer Center
See all trials for Myelodysplastic/myeloproliferative disease →